Device Trial Radar · NCT02749110
Participation in Screening for Cervical Cancer: Interest of a Self-sampling Device Provided by the General Practitioner
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
308
Actual
Start
Aug 28, 2016
Primary completion
Aug 23, 2019
Study completion Feb 23, 2021
Sponsor
- Lead sponsor
- University Hospital, LilleAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Ministry of Health, France
- First posted
- Apr 22, 2016
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- Female only, from 30 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study evaluates the benefit in women aged from 30 to 65 years, who do not participate to the French opportunistic cervical cancer screening program, of an organized screening with the proposition by the family physician of a pap-test (usual care) versus a self-collected vaginal sample (and a HPV-test). 24 family physicians will participate and will be randomized in the usual care arm (12) or in the self-sampling arm (12). Our hypothesis is that organizing the screening for these women involving their family physician will major participation, and that the self-sampling option will amplify this increase.
Conditions
- Malignant Tumor of Cervix
- Cervical Intraepithelial Neoplasia
Interventions
Vaginal self-sampling brushDevice
Self-collection by unscreened women aged from 30 to 65 of a vaginal sample with the device. After collection, the whole device is mailed in a normalized for biological samples package to the virology lab of the University Hospital of Lille where a HPV test is conducted using a Cobas 4800 technique.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of women terminating the whole diagnostic process.Time frame: For screening: 12 months; for follow-up of screened positive subjets: 18 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Doctor's office 115
Herzeele, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.